Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301).

The association between SOMs and prognosis revealed an overall trend toward a longer PFS/OS in the SOM groups, although there were minor differences depending on the definition of SOM used ( Supplementary Fig. 2 and Supplementary Table 1 ).

also in 4,871 other papers